Millendo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLND research report →
Price Chart
About the company
Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause.
- CEO
- Julia Owens
- IPO
- 2012
- Employees
- 12
- HQ
- Ann Arbor, MI, US
Get TickerSpark's AI analysis on MLND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.15M
- P/E
- -0.27
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -14.80
- EV/EBITDA
- 1.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1270.11%
- ROIC
- -386.45%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $0
- Net Income
- $-26,262,000+37.2%
- EPS
- $-6.33-322.0%
- OCF Growth
- +0.0%
- FCF Growth
- +100.0%
- 52W High
- $41.55
- 52W Low
- $1.06
- 50D MA
- $18.86
- 200D MA
- $25.14
- Beta
- 0.48
- RSI (14)
- 36
- Avg Volume
- 140.97K
No earnings-call transcripts are available for MLND yet.
- Free Float
- 76.2%
- Shares Outstanding
- 10.52M
- Float Shares
- 8.01M
of shares held by institutions
34 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Advisor Group, Inc. | 3 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 20 | Nuechterlein Carole | other | 12,000 |
| Jun 22, 20 | HOWE JOHN P MD | other | 12,000 |
| Jun 22, 20 | Gallagher Carol Giltner | other | 12,000 |
| Jun 22, 20 | NICHOL GEOFFREY | other | 12,000 |
| Jun 22, 20 | Hindman James M. | other | 12,000 |
| May 25, 20 | JOSEPH TAMARA L | other | 80,000 |
| May 25, 20 | Arbet-Engels Christophe | other | 80,000 |
| Feb 10, 20 | Arbet-Engels Christophe | other | 140,000 |
| Feb 10, 20 | Arbet-Engels Christophe | other | 0 |
| Jan 31, 20 | JOSEPH TAMARA L | other | 56,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MLND coverage
Recent articles, reports, and earnings notes.
No research on MLND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLND report →Tempest and Millendo Announce Stockholder Approval of Merger
globenewswire.com · Jun 22
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
businesswire.com · Apr 7
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
prnewswire.com · Apr 2
Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND
businesswire.com · Mar 31
MLND Stock Price Falls Over 10% Pre-Market: Why It Happened
pulse2.com · Mar 29
Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
benzinga.com · Mar 29
Tempest and Millendo Announce Proposed Merger Agreement
businesswire.com · Mar 29
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
businesswire.com · Aug 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.